Literature DB >> 33144083

Metabolic interventions: A new insight into the cancer immunotherapy.

Tao Yu1, Tianhan Dong2, Haniyeh Eyvani1, Yuanzhang Fang1, Xiyu Wang3, Xinna Zhang4, Xiongbin Lu5.   

Abstract

Metabolic reprogramming confers cancer cells plasticity and viability under harsh conditions. Such active alterations lead to cell metabolic dependency, which can be exploited as an attractive target in development of effective antitumor therapies. Similar to cancer cells, activated T cells also execute global metabolic reprogramming for their proliferation and effector functions when recruited to the tumor microenvironment (TME). However, the high metabolic activity of rapidly proliferating cancer cells can compete for nutrients with immune cells in the TME, and consequently, suppressing their anti-tumor functions. Thus, therapeutic strategies could aim to restore T cell metabolism and anti-tumor responses in the TME by targeting the metabolic dependence of cancer cells. In this review, we highlight current research progress on metabolic reprogramming and the interplay between cancer cells and immune cells. We also discuss potential therapeutic intervention strategies for targeting metabolic pathways to improve cancer immunotherapy efficacy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunometabolism; Metabolic reprogramming; Nutrients competing; Tumor microenvironment; Tumor-infiltrating lymphocytes

Mesh:

Year:  2020        PMID: 33144083      PMCID: PMC8638212          DOI: 10.1016/j.abb.2020.108659

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  198 in total

Review 1.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Inhibitory effect of tumor cell-derived lactic acid on human T cells.

Authors:  Karin Fischer; Petra Hoffmann; Simon Voelkl; Norbert Meidenbauer; Julia Ammer; Matthias Edinger; Eva Gottfried; Sabine Schwarz; Gregor Rothe; Sabine Hoves; Kathrin Renner; Birgit Timischl; Andreas Mackensen; Leoni Kunz-Schughart; Reinhard Andreesen; Stefan W Krause; Marina Kreutz
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

3.  Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.

Authors:  Lisa S Pike; Amy L Smift; Nicole J Croteau; David A Ferrick; Min Wu
Journal:  Biochim Biophys Acta       Date:  2011-06

4.  Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.

Authors:  Christos Chouaid; Lionel Bensimon; Emilie Clay; Aurélie Millier; Laurie Levy-Bachelot; Min Huang; Pierre Levy
Journal:  Lung Cancer       Date:  2018-11-23       Impact factor: 5.705

5.  Identification of small molecule inhibitors of pyruvate kinase M2.

Authors:  Matthew G Vander Heiden; Heather R Christofk; Eli Schuman; Alexander O Subtelny; Hadar Sharfi; Edward E Harlow; Jun Xian; Lewis C Cantley
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858

6.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 7.  Nitrogen Metabolism in Cancer and Immunity.

Authors:  Kiran Kurmi; Marcia C Haigis
Journal:  Trends Cell Biol       Date:  2020-03-10       Impact factor: 20.808

Review 8.  Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.

Authors:  Joseph A Clara; Cecilia Monge; Yingzi Yang; Naoko Takebe
Journal:  Nat Rev Clin Oncol       Date:  2019-12-02       Impact factor: 66.675

9.  Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.

Authors:  Richard W Joseph; Alicia C Shillington; Todd A Lee; Cynthia P Macahilig; Scott J Diede; Vaidehi Dave; Qing Harshaw; Emilie Scherrer; Frank Xiaoqing Liu
Journal:  J Med Econ       Date:  2019-12-09       Impact factor: 2.448

10.  Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.

Authors:  Dan J M Nguyen; George Theodoropoulos; Ying-Ying Li; Chunjing Wu; Wei Sha; Lynn G Feun; Theodore J Lampidis; Niramol Savaraj; Medhi Wangpaichitr
Journal:  Mol Cancer Res       Date:  2019-10-18       Impact factor: 5.852

View more
  1 in total

Review 1.  Proline dehydrogenase in cancer: apoptosis, autophagy, nutrient dependency and cancer therapy.

Authors:  Yating Liu; Chao Mao; Shuang Liu; Desheng Xiao; Ying Shi; Yongguang Tao
Journal:  Amino Acids       Date:  2021-07-20       Impact factor: 3.520

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.